FDA Gives Psilocybin Clinical Studies Breakthrough Therapy Status
The FDA recognized psilocybin, the psychoactive compound in magic mushrooms, with “Breakthrough Therapy” designation for clinical trials studying its use for treatment-resistant depression by a company called Compass Pathways. The group plans to treat patients in Europe and North America over the next year in placebo-controlled studies to determine proper dosage and treatment methods.
Since hallucinogenic drugs were given Schedule I designation in 1966, psilocin and psilocybin have been villainized by the media and politicians who claim it has a high potential for abuse and no medical application. But recent studies from esteemed research institutions, including Johns Hopkins and London’s Imperial College, have helped ease misconceptions and stigma surrounding the drug, and now government regulatory bodies are seeing its potential.
Compass Pathways, a life sciences company founded in 2016 whose focus is to “accelerate patient access to evidence-based innovation in mental health,” specifically through research with psilocybin, was given the go-ahead by the FDA back in August, but the recent designation was an unexpected acknowledgment, according to some of those involved in its research.
According to the FDA, “Breakthrough Therapy” means it reviewed the findings of researchers it granted use of the drug to and viewed their results as:
“Preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.”
Once this designation is given, the FDA expedites the development and review of the drug, hopefully allowing medical professionals to soon begin implementing it as a legal, viable treatment and eventually change the scheduling of the drug.
Dr. Roland Griffiths, one of the foremost researchers in government-sanctioned studies of hallucinogenic drugs, told Inverse he’s hopeful the regulatory approval will change, though he doesn’t envision it becoming available from a pharmacy anytime soon, if ever.
Griffiths and his colleagues have mostly advocated for its use in controlled settings with guided sessions from a trained psychologist. He’s also stated he believes it can be a dangerous drug when taken by those with certain pre-existing mental illnesses, notably schizophrenia.
But now that studies have shown psilocybin to act as a “reset mechanism” in the brain for those suffering from severe forms of depression, this latest recognition from the FDA may allow psilocybin treatment to become available for those desperately needing it. This breakthrough may also pave the way for FDA trials with other psychedelic substances, such as LSD, currently studied by Griffiths and others in his field.
For more on Dr. Roland Griffith’s and other cutting edge work studying clinical treatments with psychedelic substances, check out this episode of Psychedelica:
About the Author
Ketamine Therapy Proves Powerful For Treatment-Resistant Depression
A powerful FDA-approved anesthetic drug once used mainly in operating rooms and on the battlefield is quickly gaining ground as one of the most promising therapies for treatment-resistant mental health conditions.
First discovered as an anesthetic in the 1950s, ketamine has been used in the treatment of a wide range of physical conditions, especially pain management. Starting in the early 1970s, doctors began to find that it can also be very effective in alleviating mental health issues such as depression, anxiety, PTSD, and addiction. Today it is ever more frequently being studied and legally used as an off-label medication to manage conditions that are particularly resistant to treatment with conventional pharmaceuticals.
The latest in a series of recent studies has found that ketamine can quickly and dramatically decrease chronic and suicidal thoughts. Dr. Naveen Thomas is a psychiatrist who has been using ketamine in his practice for years.
“I and many of my colleagues have of course had tremendous success in using ketamine in people who are really suffering from depression. I’ve had a lot of success in treating people with Post-traumatic Stress Disorder,” Dr. Naveen said.
“And some of these folks have spent years and years doing absolutely the best they could using such a wide variety of the conventional treatments, be they various medication treatments, be they various forms of psychotherapy. We’ve seen really wonderful effects.”
